FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease

SILVER SPRING, Md., May 11, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the first FDA-approved…

Leave a Reply

Your email address will not be published. Required fields are marked *